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Abstract 
Rhenium and ruthenium complexes containing N-heterocylic carbene (NHC) ligands and 
conjugated to indomethacin were prepared. The anticancer properties were probed against 
pancreatic cell lines, revealing a remarkable activity of the rhenium fragment as anticancer agent. 
The ruthenium complexes were found to be inactive against the same pancreatic cancer cell lines, 
either alone or in conjugation with indomethacin. An in depth biological study revealed the origin 
of the anticancer properties of the rhenium tricarbonyl fragment, of which a complete elucidation 
had yet to be achieved. It was found that the rhenium complexes induce cell cycle arrest at the 
G2/M phase by inhibiting the phosphorylation of Aurora-A kinase. A preliminary study on the 
structure-activity relationship on a large family of these complexes revealed that the anticancer 
properties are mainly associated with the lability of the ancillary ligand, with inert complexes 
showing limited to no anticancer properties. 
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Cancer is one of the leading causes of death and, as such, the drive to discover new anti-cancer 
drugs is an expanding area of research. One class of frontline anti-cancer agents are the platinum-
based drugs cisplatin, carboplatin, and oxaliplatin, which are extremely effective at eradicating 
cancer cells, but suffer from severe side-effects and poor activity against platinum-resistant 
cancers. Other organometallic and inorganic complexes have been studied extensively as an 
alternative to organic based drugs.1-4 In this context, complexes of gold, platinum, and ruthenium 
have attracted considerable attention and have been shown to be particularly effective, often by 
targeting mitochondria or DNA.5-9 Organometallic complexes of rhenium that contain the 
chemically robust Re(CO)3 fragment have recently shown potential as cytotoxic agents, but they 
have been far less studied. Furthermore, their mechanism of action has not been established in 
details yet, which hinders the systematic design and investigation of targeted rhenium complexes 
as anticancer agents. All the reported cytotoxic rhenium complexes contain bidentate or 
tridentate ligands of nitrogen, oxygen, and phosphorus donors, a chemical design that seems to be 
predominantly inspired by the use of these species as luminescent cellular markers.10 Other rare 
examples include rhenium complexes bearing cyclopentadienyl ligands.11 
We and others have been recently interested in the investigation of the photochemical properties 
of rhenium complexes bound to N-heterocyclic carbene (NHC) ligands.12-18 Surprisingly, this 
relatively new class of complexes has never been assessed in a biological context, either as 
luminescent cellular markers or anticancer agents. We therefore endeavored to evaluate rhenium 
NHC species against several pancreatic cell lines (one of the most aggressive cancers with a five-
year survival rate around 5%) in direct comparison with ruthenium arene complexes, whose 
structural motif has shown anticancer properties in previous investigations.19 For this scope, we 
decided to study the complexes alone or conjugated to the nonsteroidal anti-inflammatory drug 
(NSAID) indomethacin. This chemical design was inspired by the fact that molecular units 
comprising a metal fragment and NSAID have been previously reported to enhance anticancer 
properties.20-26 Remarkably, it was found that the rhenium complexes were active against 
pancreatic cell lines, while the ruthenium complexes did not show any significant activity.  
Furthermore, conjugation to indomethacin did not seem to enhance the anticancer activity, which 
was traced back exclusively to the presence of the Re(CO)3 fragment. With this study, for the first 
time, it was possible to elucidate that the anticancer properties of the rhenium tricarbonyl 
fragment originate from the lability of the monodentate ancillary ligand coordinated to the 
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Figure 1. Structures of rhenium and ruthenium NHC complexes. 
 
A detailed description of the synthesis of the complexes shown in Figure 1 is given in the 
Supporting Information. Briefly, indomethacin-functionalized azolium salts 1.Br and 2.BPh4 were 
prepared and then reacted with Re(CO)5Br to afford complexes 3, 4a, 4b. To the best of our 
knowledge, this is the first example of an abnormal carbene complex of rhenium. The 
spectroscopic evidence for complex 4b containing an abnormal carbene is discussed in the 
Supporting Information. The X-ray structure of complex 3 can be seen in Figure 2, with additional 
data found in the Supporting Information. Reaction of 1.Br and 2.BPh4 with Ag2O gave complexes 
5 and 6, which were treated with [Ru(cymene)Cl]2 (cymene = 1-methyl-4-(propan-2-yl)benzene) to 




Figure 2. X-Ray structure of complex 3 with anion and disordered components omitted and 
displacement ellipsoids at the 50% probability level. 
 
The biological activity of the rhenium and ruthenium complexes were tested on a panel of human 
pancreatic cancer cell lines comprising HPAF-II, ASPC1, and CFPAC. To understand if the metal-
indomethacin conjugates possessed dual activity, complexes 9 and 10.PF6 as well as indomethacin 
alone were tested against the same cells. Strikingly, complex 4b and indomethacin were 
ineffective at concentrations up to 10 M (Figure S11) while the ruthenium complexes were 
ineffective up to 75 – 100 M (Figure S12). Contrarily, rhenium complexes 3, 4a, and 9 at 10 M 
showed almost complete inhibition. To determine the effect of the rhenium compounds on cell 
growth, these cell lines were treated with increasing concentrations of specific rhenium 
compounds (Figure S13). We observed that treatment with each inhibitor significantly and dose-
dependently reduced the number of cells, as assessed by cell counting after 72 hour incubation in 
complete media containing 10% FBS, with IC50 values for 3, 4a, 9, and carboplatin as control shown 
in Table 1. The IC50 values indicate that the rhenium compounds are remarkably active given the 
robust nature of these particular pancreatic cancer cell lines, with similar or slightly higher activity 
than carboplatin. Importantly, while the rhenium compounds almost completely inhibit all 
pancreatic cancer cell lines at 10 M, around 20% of all the pancreatic cancer cells in each line 
are resistant to carboplatin up to 50 M. Furthermore, since compound 9 was as active, or more 
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active, than the indomethacin conjugates 3 and 4a, we can confidently conclude that it is the 
rhenium complex that is responsible for pancreatic cancer cell inhibition. To the best of our 
knowledge, this is the first example of rhenium-NHC complexes displaying anti-cancer activity. 
While there are a number of rhenium complexes of diimine ligands that display moderate to high 
anti-cancer activity, as recently reviewed by Gasser, only two reports describe their activity against 
pancreatic cancer, although no explanation of the mechanism was given.27,28 Interestingly, the 
active compounds, and in particular 9, seem to only be effective at higher concentrations (above 
10 M) when tested on healthy human embryonic kidney 293T cells (HEK293T) (Figure S14), 
indicating a moderate selectivity toward pancreatic cancer cells over healthy cells. To further 
validate these results, pancreatic cancer cells were treated with 3, 4a, and 9 and cell viability 
assessed by the Alamar blue assay.29 The three compounds almost completely impair viability of 
all pancreatic cancer cell lines tested, while being less active against HEK293T (see Figure S15-17). 
Overall, these results demonstrate the great efficacy of the novel rhenium compounds in blocking 
proliferation/viability of different pancreatic cancer cells. 
 
Table 1. IC50 (M) values for compounds 3, 4a, and 9 against pancreatic cancer cell lines.  
Compound ASPC1 HPAF-II CFPAC HEK293T 
3 7.9 ± 1.4 6.0 ± 2.0 6.0 ± 1.8 11.8 ± 2.3 
4a 9.4 ± 3.5 4.8 ± 0.8 5.4 ± 1.4 8.6 ± 0.3 
9 4.0 ± 1.2 5.6 ± 0.6 5.7 ± 2.8 14.8 ± 2.4 
Carboplatin 6.8 ± 2.0 8.7 ± 4.3 7.4 ± 1.2 45a, 30 
a Literature data. 
 
The effect of 3, 4a, and 9 on the growth rate of the pancreatic cancer cells was determined by the 
Incucyte Zoom real-time video imaging system. Treatment with 3, 4a, and 9 had a significant 
inhibitory effect on the growth of pancreatic cancer cells in a dose and time dependent manner 
compared to the vehicle-treated cells. Representative video of ASPC1 control cells and treated 
with 10 M 9 are shown (Suppl. video). Moreover, quantification of viable cells after 72 hours of 
treatment showed that 3, 4a, and 9 significantly decreased the percentage of viable pancreatic 
cancer cells. When pancreatic cancer cells nuclei were probed for active caspase 3 or 7 (#4440 
IncuCyte), and cell membrane integrity assessed via Red CytoTox permeabilization (#4632 
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Incucyte), no major differences were observed in cells treated with 3 and 9 compared to the 
vehicle control (Figure S18 and S19). In contrast, compound 4a induced cell apoptosis as 
confirmed using a different assay (Caspase-Glo® 3/7 Assay System). Taken together, these results 
provide evidence that the rhenium compounds 3 and 9 do not induce apoptosis or disrupt the cell 
membrane in pancreatic cancer cells, but act as cytostatic drugs. 
Our next objective was to further characterize the cell death process upon 3, 4a, and 9 treatment. 
Since treatment with 3 and 9 did not result in significant increase in caspase-3 activity, we wanted 
to assess the mechanism of action of rhenium compounds. Microscopic analysis of the pancreatic 
cancer cells after treatment with 3 and 9 did not reveal morphological changes associated with 
apoptosis, instead we observed the presence of multinucleated cells. The presence of 
multinucleated cells suggests cell cycle arrest. Cell cycle analysis after 3, 4a, and 9 treatment 
revealed a significant decrease in the number of cells at G1 with high percentage of cells that were 
arrested in G2/M phase (see Figure S20). Aurora-A plays a crucial role in mitotic entry and G2 
checkpoint control. Dysregulation of Aurora-A induces abnormal G2-M transition in mammalian 
cells leading to chromosome instability and eventually in the development and progression of 
malignant tumors. In addition, it has been shown that Aurora A is overexpressed in different 
tumors including pancreatic cancer. Therefore, we tested whether the rhenium compounds were 
able to inhibit the phosphorylation of Aurora-A in pancreatic cancer cells. As shown in Figure 3, 10 
M of 3, 4a, and 9 completely inhibit the phosphorylation of Aurora A. Several studies have shown 
amplification and overexpression of Aurora-A kinase gene (AURKA) in several cancers. Increasing 
evidence demonstrate that Aurora-A plays a key role in regulating cell cycle and mitosis, as well as 
a number of important oncogenic signaling pathways. Therefore, there is an increasing interest in 
developing novel Aurora-A inhibitors, and some have moved to phase III clinical trials in 
lymphomas. However, despite the increasing evidence of the role played by Aurora-A in many 
tumors, there has been a little progress in the clinical development of Aurora A inhibitors in solid 
tumors. Therefore, it is imperative to identify novel Aurora-A inhibitors to progress to clinical 
trials. To assess the tumorigenicity of the rhenium compounds in vitro against a three dimensional 
tumor model, we performed a three-dimensional soft agar colony formation assay. Consistently, 
treatment of ASPC1, HPAF-II and CFPAC with 9 inhibited anchorage-independent growth as it 





Figure 3. Regulation of Aurora-A kinase activity by Rhenium complexes compared to blank (0.1% 
DMSO) and positive controls (nocodazole and gemcitabine). Western blot analysis of activated 
phosphoAurora-A (Threonine 288) in AsPC1 cells treated for 24 hours with 3, 4a and 9.  Samples 
were analyzed for (top to bottom) Aurora-A phosphorylation (Thr-288), total Aurora-A protein 
(Aurora-A) and -Actinin. The same blot used for phospho-Aurora-A was stripped and then 
reprobed with Anti-Aurora-A antibody. Results are representative of three independent 
experiments.  
 
A preliminary structure-activity relationship (SAR) investigation was conducted by screening 17 
complexes of the rhenium NHC family along with the precursor ligand imidazolium salt and the 
benchmark luminescent rhenium complex fac-[Re(CO)3(phen)Cl] (phen=1,10-phenanthroline). The 
study clearly demonstrates that the anticancer activity originates from the degree of lability of the 
ancillary ligand, with inert complexes displaying limited to no anticancer activity (see 
Supplementary Information and Figure S22-24 for a more detailed discussion). Consistently, the 
two most active rhenium carbene complexes identified from the SAR were found to inhibit the 
phosphorylation of Aurora-A in AsPC1 cells, while fac-[Re(CO)3(phen)Cl], which contains a 
significantly less labile chloro ligand, was inactive (Figure S25).  
Our results reinforce the potential usefulness of tricarbonyl rhenium complexes as potent anti-
cancer agents against extremely robust pancreatic cancer cells. Most importantly, we have 
demonstrated, for the first time, that this class of complexes acts as cytostatic drugs by inducing a 
cell cycle arrest at the G2/M phase associated with inhibition of the phosphorylation of Aurora-A 
kinase. For design purpose, our study indicates that the anticancer activity of the rhenium 
complexes originates from the lability of the ancillary ligand. These results shed some light into the 
mechanism of anticancer activity of tricarbonyl rhenium complexes, which was previously largely 
unknown due to a lack of systemic studies. This class of complexes could have broad application as 
 8 
anti-cancer drugs. It will be interesting to investigate both in vitro and in vivo the cytotoxic 
properties of these complexes and to assess in vivo their antitumor activity alone or in 
combination with other known chemotherapeutic agents. 
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Rhenium tricarbonyl complexes bound to N-heterocyclic carbene ligands exhibit antitumor 
properties against pancreatic cancer, revealing a mechanism of action based on induction of 
G2/M cell cycle arrest and blockade of Aurora-A Kinase phosphorylation. 
 
 
 
 
